Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ARDX - ARDELYX, INC.


IEX Last Trade
4.65
-0.130   -2.796%

Share volume: 400
Last Updated: Fri 27 Dec 2024 03:30:01 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -1.15%

PREVIOUS CLOSE
CHG
CHG%

$4.78
-0.13
-2.72%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
22%
Profitability 25%
Dept financing 8%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
1.31%
1 Month
-13.27%
3 Months
-27.04%
6 Months
-24.06%
1 Year
-28.28%
2 Year
92.53%
Key data
Stock price
$4.65
P/E Ratio 
0.00
DAY RANGE
$4.78 - $4.78
EPS 
$0.00
52 WEEK RANGE
$4.70 - $10.13
52 WEEK CHANGE
-$27.73
MARKET CAP 
1.455 B
YIELD 
N/A
SHARES OUTSTANDING 
235.428 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/29/2024
BETA 
1.75
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$5,297,221
AVERAGE 30 VOLUME 
$3,967,498
Company detail
CEO: Michael G. Raab
Region: US
Website: ardelyx.com
Employees: 90
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation. It is also developing RDX013, a potassium secretagogue, for the. treatment of elevated serum potassium, or hyperkalemia, among certain patients with kidney and/or heart disease.

Recent news